The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Accelerating Non-Alcoholic Steatohepatitis (NASH) Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking a compound annual growth rate (CAGR) of 34.7%. Factors contributing to this growth in the historic duration include an increase in NASH cases, an obesity outbreak, rising awareness and diagnoses, alterations in lifestyle and eating habits, along with the development of healthcare infrastructure.

Non-Alcoholic Steatohepatitis (NASH) Market Size Forecast: What's the Projected Valuation by 2029?
The market for non-alcoholic steatohepatitis (NASH) is set to experience considerable expansion in the coming years, reaching a projected "$18.55 billion by the year 2029" with a compound annual growth rate (CAGR) of "32.3%". This anticipated surge during the forecast period can be linked to advancements in medicine for NASH, an increase in NASH screening initiatives, a rise in health care spending, joint research endeavors, and supportive government policies. Key trends anticipated to shape the forecast period include a focus on lifestyle adjustments and patient awareness, a spike in collaborative efforts in clinical studies, progress in regulatory pathways, and the incorporation of artificial intelligence into diagnostic procedures and tracking.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

What Are the Drivers Transforming the Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (NASH) market is gaining momentum due to the escalating incidence of obesity. Characterized by abnormal or excess accumulation of fat, obesity increases health risks and denotes a weight higher than what is considered healthy or normal for a given height. With the prevalence of non-alcoholic fatty liver disease swelling on account of this obesity epidemic, NASH could potentially emerge as the commonest reason for severe liver disease in the coming decades, thereby fuelling the demand for treatments and associated drugs for NASH. For instance, the World Health Organization (WHO), a UK-based global public health body, reported in March 2024 that around 2.5 billion adults, aged 18 or more, were considered overweight in 2022, with 890 million among them suffering from obesity. Hence, rising obesity instances will drive the expansion of the non-alcoholic steatohepatitis (NASH) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Non-Alcoholic Steatohepatitis (NASH) Market?
The big players in the non-alcoholic steatohepatitis (NASH) sector are creating thyroid hormone receptor-beta (THR-beta) agonists to advance liver metabolism, decrease build up of liver fat and enhance liver function. THR-beta agonists are substances that precisely trigger the thyroid hormone receptor-beta subtype, an important receptor for regulating metabolism, growth, and development. For example, the US's Food and Drug Administration sanctioned Rezdiffra (resmetirom), a THR-beta agonist, as the initial treatment for adult noncirrhotic NASH patients displaying moderate to advanced liver fibrosis in March 2024. Rezdiffra, by specifically triggering the THR-beta receptor, helps manage lipid metabolism, thereby lowering intrahepatic triglycerides and overall liver fat accrual.

Which Segments in the Non-Alcoholic Steatohepatitis (NASH) Market Offer the Most Profit Potential?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented -

1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral

Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Which Firms Dominate the Non-Alcoholic Steatohepatitis (NASH) Market by Market Share and Revenue in 2025?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Which Regions Offer the Highest Growth Potential in the Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.